British doctors to start new phase III trial with Pharmexa's GV1001

Referred to as the TeloVac trial, the recently initiated Phase III trial is a so-called investigator-sponsored trial. The trial is designed and managed by the Pancreas Cancer Sub-group of the National Cancer Research Institute in the UK, with Dr. Gary Middleton of the Royal Surrey County Hospital as Chief Investigator, whilst the group of Principal Investigators include Professor David Cunningham of the Royal Marsden Hospital and Professor John Neoptolemos of the Royal Liverpool University Hospital. Up to 80 UK cancer centres are participating in the trial. The trial is testing GV1001, a new immunotherapeutic drug for pancreatic cancer developed by Danish-based biotech company...

Want to see the full article?

• Purchase this article for only $3.00